Imaging: General & Cancer Specific MRI MRI-S PET vs CT Color Doppler Ultrasound Prostascint Scan Bone Scan
Approaches & Strategies Prevention of Metastasis & Angiogenesis Immune Enhancement Hormonal & Metabolic Modulation Direct Cytotoxicity Antioxidants, Anti Inflammatory & Anti Microbial Detoxification Circulation & Hyper Viscosity Improvement Redifferentiation
PREVENTION OF METASTASIS AND ANGIOGENESIS WITH MODIFIED CITRUS PECTIN
MODIFIED CITRUS PECTIN PROSTATE CANCER RESEARCH Published Clinical and Preclinical Data
Inhibition of Spontaneous Metastasis in a Rat Prostate Model by Oral Administration of Modified Citrus Pectin Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle, TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A Wayne State University School of Medicine, Detroit, MI, USA J Natl Cancer Inst 1995 87(5):348-53. Method: MCPs inhibition of prostate cell adhesion to endothelial cells. 0.1% and 1.0% MCP in rats drinking water; controls had plain water Results: Significant reduction in lung metastases -- 50% reduction in 0.1% group; 56% reduction in 1.0% group (P<0.03 & P<0.001). Conclusion: MCP acted as potent inhibitor of spontaneous prostate carcinoma metastasis.
Effect of Modified Citrus Pectin on PSA Doubling Time in Prostate Cancer Patients: A Pilot Clinical Trial Method: MCP 15 g/day to patients with biochemical relapse post local therapy. PSA Doubling Time (PSADT) evaluated at intervals. Results: MCP significantly increased PSADT in prostate cancer patients. Strum S, Scholz M, McDermed J, McCulloch M, Eliaz, I Prostate Oncology Specialist, Marina del Rey, CA, USA Amitabha Medical Clinic & Healing Center, Sebastopol, CA, USA EcoNugenics, Santa Rosa, CA, USA. International Conference on Diet & The Prevention of Cancer 1999, Tampere, Finland.
Patient MCP Use (Months) PSADT ChangeStatus Patient 1 5193% Response Patient 2 6193% Response Patient 3 380% Response Patient 4>1555% Response Patient 5 66% P. Response Patient 6 6-7% Stable Disease Patient 7 5-69% No Response Pilot Clinical Results: MCPs Effect on PSA Doubling Time
Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI Healing Touch Oncology, Marina del Rey, CA, USA Prostate Cancer & Prostatic Disease 2003;6(4):301-4. Method: 10 men with biochemical prostate cancer relapse used MCP: 15g daily for 1 year. Results: MCP significantly increased PSADT in 7 out of the 10 participants (p<0.01).
968 % * * Phase II Study: PSADT Results After 1 Year
Using Splines to Detect Changes in PSA Doubling Times Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M, Healing Touch Oncology, Marin del Ray, CA, Department of Statistics, UCLA, CA, The Prostate 2003 54:88-95.
MCP Typical Patient Results
Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C, Albert-Ludwigs-University in Freiburg, Germany, Sonnenberg-Klinik, Bad Sooden-Allendorf, Germany Method: MCP 15g daily. Results: 49 patients with advanced solid tumors. 29 evaluated after 2 months -- 21% showed stabilization & improvements in quality of life. One patient w/ metastasized prostate carcinoma showed 50% decrease in PSA, with significant increase in quality of life & decrease in pain. Conclusion: MCP shows clinical benefits & improvements in quality of life in advanced cancer patients.
IMMUNE ENHANCEMENT IN PROSTATE CANCER TREATMENT
Direct Cytotoxicity in Prostate Cancer Treatment Curcumin, Green Tea Extracts Ban Zhi Lian (Scutellariae barbata) Artemisinin MCP Honokiol MCP + Honokiol Others
Effect of Honokiol on Growth of PC3 Cells (Pre-Published data)
Synergistic Effect of MCP & Honokiol on PC3 Cell Line Migration (Pre-Published Data)
BA Poly Botanical & MCP Effect on Migration of Human Prostate Cancer Cells The invasive behavior of PC3 evaluated using migration assay in the presence of (A) MCP (mg/mL) & (B) MCP (mg/mL) plus Poly Botanical (10 ug/mL). Poly Botanical
CIRCULATION AND HYPERVISCOSITY IMPROVEMENT IN PROSTATE CANCER TREATMENT